Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...

The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...

There is tremendous positive momentum underway at Catalent, and I believe that our future is even brighter as a private company with the support of Novo Holdings." "With the European Commission ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holding ...